These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3838406)

  • 1. Active and passive changes in coronary diameter after vasodilation with SIN-1, the active metabolite of molsidomine.
    Schulz W; Kober G; Bernauer R; Kaltenbach M
    Am Heart J; 1985 Mar; 109(3 Pt 2):694-9. PubMed ID: 3838406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diameter changes of epicardial coronary arteries and coronary stenoses after intracoronary application of SIN 1, a molsidomine metabolite].
    Schulz W; Wendt T; Scherer D; Kober G
    Z Kardiol; 1983 Jul; 72(7):404-9. PubMed ID: 6613236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new long-acting coronary artery dilator molsidomine and its metabolite SIN-1.
    Sobolski J; Vandermoten P; Stoupel E; Berkenboom G; Degre S
    Am Heart J; 1985 Mar; 109(3 Pt 2):700-3. PubMed ID: 3838407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting coronary vasodilatory action of the molsidomine metabolite Sin 1: a quantitative angiographic study.
    Serruys PW; Deckers JW; Luijten HE; Reiber JH; Tijssen JG; Chadha D; Hugenholtz PG
    Eur Heart J; 1987 Mar; 8(3):263-70. PubMed ID: 3582385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention with molsidomine of coronary artery spasm caused by alkalosis.
    Weber S; Kahan A; Pailleret JJ; Guérin F; Degeorges M
    Am Heart J; 1985 Mar; 109(3 Pt 2):704-7. PubMed ID: 3838408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of vasodilation by molsidomine.
    Kukovetz WR; Holzmann S
    Am Heart J; 1985 Mar; 109(3 Pt 2):637-40. PubMed ID: 2983523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active and passive coronary vasodilation after intracoronary and sublingual nitroglycerin.
    Schulz W; von Anderten W; Reiber JH; Bernauer R; Kaltenbach M; Kober G
    Z Kardiol; 1983; 72 Suppl 3():82-6. PubMed ID: 6421018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitroglycerin-resistant coronary spasm treated with intracoronary linsidomine chlorhydrate (SIN-1).
    Drobinski G; Montalescot G
    Eur Heart J; 1990 May; 11(5):472-5. PubMed ID: 2112998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of coronary arteries to nitrates, the EDRF-donor SIN-1, and calcium antagonists.
    Schulz W; Kober G
    Basic Res Cardiol; 1991; 86 Suppl 2():233-41. PubMed ID: 1953615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological basis of therapy with molsidomine].
    Bassenge E
    Herz; 1982 Oct; 7(5):296-306. PubMed ID: 6897544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracoronary linsidomine abolishes acetylcholine-induced vasoconstriction of epicardial coronary arteries.
    Dubois-Rande JL; Dupouy P; Geschwind H; Castaigne A; Adnot S
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):462-7. PubMed ID: 7504139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of molsidomine and its metabolite SIN-1 on coronary vessel tone, platelet aggregation, and eicosanoid formation in vitro--inhibition of 12-HPETE biosynthesis.
    Darius H; Ahland B; Rücker W; Klaus W; Peskar BA; Schrör K
    J Cardiovasc Pharmacol; 1984; 6(1):115-21. PubMed ID: 6199592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and hemodynamic effects of the new dilator drug molsidomine.
    Malcolm AD
    Am Heart J; 1985 Mar; 109(3 Pt 2):674-7. PubMed ID: 3883734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, randomized, placebo-controlled study of molsidomine in patients with stable effort angina receiving beta-blocker therapy with atenolol.
    De Backer GG; Derese A
    Am Heart J; 1985 Mar; 109(3 Pt 2):678-81. PubMed ID: 3883735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of intracoronary injection of SIN-1 on vasoconstriction of epicardial arteries induced by acetylcholine].
    Dubois-Randé JL; Adnot S; Dupouy P; Castaigne A; Geschwind H
    Arch Mal Coeur Vaiss; 1993 Jun; 86(6):881-7. PubMed ID: 8274060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans.
    Meinertz T; Brandstätter A; Trenk D; Jähnchen E; Ostrowski J; Gärtner W
    Am Heart J; 1985 Mar; 109(3 Pt 2):644-8. PubMed ID: 3838400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection by carbocromene and molsidomine against arrhythmias occurring during coronary artery occlusion and reperfusion in dogs.
    Fiedler VB; Kettenbach B; Göbel H; Nitz RE
    J Cardiovasc Pharmacol; 1985; 7(5):964-70. PubMed ID: 2413309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic GMP as the mediator of molsidomine-induced vasodilatation.
    Kukovetz WR; Holzmann S
    Eur J Pharmacol; 1986 Mar; 122(1):103-9. PubMed ID: 3007172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activity of molsidomine in experimental models of ischemic cardiac disease.
    Nitz RE; Martorana PA
    Am Heart J; 1985 Mar; 109(3 Pt 2):631-6. PubMed ID: 3919549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of molsidomine in the long-term treatment of exertional angina pectoris and chronic congestive heart failure.
    Rudolph W; Dirschinger J
    Am Heart J; 1985 Mar; 109(3 Pt 2):670-4. PubMed ID: 3883733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.